Herzliya, Israel and Calgary, Alberta–(Newsfile Corp. – January 20, 2022) – Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the “Company” or “Innocan“), is pleased to provide an update on its research into CBD loaded liposomes using Innocan’s LPT platform. Innocan’s core goal is to develop a technology that combines the advantages of two well-known drug and delivery system to create a novel drug product that can be used for vast array of diseases.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/110858
Powered by WPeMatico
